Education
About Us
Working with TipRanks
Follow Us
Repligen Corp (RGEN)
NASDAQ:RGEN
RGEN Stock Chart & Stats
$145.66
$0.11(0.07%)
At close: 4:00 PM EST
$145.66
$0.11(0.07%)
Day’s Range― - ―
52-Week Range$102.97 - $182.52
Previous CloseN/A
Volume111.19K
Average Volume (3M)1.06M
Market Cap
$8.04B
Enterprise Value$7.50B
Total Cash (Recent Filing)$708.86M
Total Debt (Recent Filing)$686.06M
Price to Earnings (P/E)5667.7
Beta1.03
Next Earnings
Feb 25, 2026EPS Estimate
0.44Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.46
Shares Outstanding56,290,750
10 Day Avg. Volume968,754
30 Day Avg. Volume1,057,829
Financial Highlights & Ratios
PEG Ratio1.84
Price to Book (P/B)4.08
Price to Sales (P/S)12.69
P/FCF Ratio56.51
Enterprise Value/Market Cap0.93
Enterprise Value/Revenue11.12
Enterprise Value/Gross Profit22.97
Enterprise Value/Ebitda55.30
Forecast
1Y Price Target
$183.36Price Target Upside25.88% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering15
EPS Forecast (FY)1.67
Revenue Forecast (FY)$732.35M
Bulls Say, Bears Say
Bulls Say
Geographic And Segment ExpansionHighlights for 3Q25 for Repligen included sales growth in all geographic areas and business segments, especially Asia-Pacific with 50% growth.
Revenue GrowthRepligen reported solid 3Q25 operational results, delivering outperformance from both a revenue and earnings perspective.
Strategic PartnershipsRepligen established a strategic partnership with Novasign to develop and integrate Novasign’s digital twin capabilities into Repligen filtration systems.
Bears Say
Earnings Growth ChallengesHigher fixed costs and higher contributions from recent acquisitions and new products may dampen earnings growth in the near future despite expected revenue growth.
Margin PressuresThe forecast for 2025 adjusted operating margin and adjusted EBITDA margin has been lowered, indicating some financial headwinds.
Market SentimentShares ended the day down nearly 6%, attributed to the EBITDA/EPS guide-down and management signaling that elevated operating expense levels will continue near term.
Repligen News
RGEN FAQ
What was Repligen Corp’s price range in the past 12 months?
Repligen Corp lowest stock price was $102.97 and its highest was $182.52 in the past 12 months.
What is Repligen Corp’s market cap?
Repligen Corp’s market cap is $8.04B.
When is Repligen Corp’s upcoming earnings report date?
Repligen Corp’s upcoming earnings report date is Feb 25, 2026 which is in 104 days.
How were Repligen Corp’s earnings last quarter?
Repligen Corp released its earnings results on Oct 28, 2025. The company reported $0.46 earnings per share for the quarter, beating the consensus estimate of $0.422 by $0.038.
Is Repligen Corp overvalued?
According to Wall Street analysts Repligen Corp’s price is currently Undervalued.
Does Repligen Corp pay dividends?
Repligen Corp does not currently pay dividends.
What is Repligen Corp’s EPS estimate?
Repligen Corp’s EPS estimate is 0.44.
How many shares outstanding does Repligen Corp have?
Repligen Corp has 56,290,750 shares outstanding.
What happened to Repligen Corp’s price movement after its last earnings report?
Repligen Corp reported an EPS of $0.46 in its last earnings report, beating expectations of $0.422. Following the earnings report the stock price went down -5.916%.
Which hedge fund is a major shareholder of Repligen Corp?
Currently, no hedge funds are holding shares in RGEN
Repligen Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$183.36 (25.88% Upside)
$183.36 (25.88% Upside)
Blogger Sentiment
Bullish
RGEN Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 175.7K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $3.3M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 6.5%
Last 30 Days ▲ 6.7%
Last 30 Days ▲ 6.7%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
3.52%
12-Months-Change
Fundamentals
Return on Equity
0.08%
Trailing 12-Months
Asset Growth
3.29%
Trailing 12-Months
Company Description
Repligen Corp
Repligen Corporation (RGEN) is a bioprocessing company that specializes in developing and manufacturing high-purity products for the biopharmaceutical industry. The company operates primarily in the life sciences sector, focusing on enabling the production of biologic drugs through its innovative technologies and products. Repligen's core offerings include chromatography resins, filtration systems, and various tools that enhance the efficiency and effectiveness of bioprocessing workflows. Its products are utilized in the production of monoclonal antibodies, therapeutic proteins, and vaccines, catering to a growing demand in the biopharmaceutical market.
RGEN Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflects a strong performance with significant organic growth, record order growth, and improved financial guidance. However, challenges remain, particularly with the China market and gene therapy headwinds. Despite these challenges, the company is optimistic about its strategic investments and future growth opportunities.View all RGEN earnings summariesRGEN Revenue Breakdown
44.00% North America
37.00% Europe
19.00% APAC/Other
RGEN Stock 12 Month Forecast
Average Price Target
$183.36
▲(25.88% Upside)
Technical Analysis
AptarGroup
―
Merit Medical Systems
―
Teleflex
―
Stevanato Group
―
Bausch + Lomb Corporation
―
Ownership Overview
0.62% Insiders
33.47% Mutual Funds
1.09% Other Institutional Investors
44.20% Public Companies and
Individual Investors